mulpleo (previously lusutrombopag shionogi)
shionogi b.v. - lusutrombopag - trombocytopeni - hemostatika - mulpleo är indicerat för behandling av svår trombocytopeni hos vuxna patienter med kronisk leversjukdom som genomgår invasiva ingrepp.
hemosilate vet 125 mg/ml injektionsvätska, lösning
ecuphar veterinaria s.l.u - etamsylat - injektionsvätska, lösning - 125 mg/ml - etamsylat 125 mg aktiv substans; natriummetabisulfit hjälpämne; natriumsulfit (vattenfritt) hjälpämne; bensylalkohol hjälpämne - får, get, hund, häst, katt, nöt, svin
doptelet
swedish orphan biovitrum ab (publ) - avatrombopag maleate - trombocytopeni - hemostatika - doptelet är indicerat för behandling av svår trombocytopeni hos vuxna patienter med kronisk leversjukdom som är planerade att genomgå ett ingrepp. doptelet is indicated for the treatment of primary chronic immune thrombocytopenia (itp) in adult patients who are refractory to other treatments (e. kortikosteroider, immunoglobuliner).
tavlesse
instituto grifols s.a. - fostamatinib dinatrium - trombocytopeni - andra systemiska hemostatika - tavlesse är indicerat för behandling av kronisk immun trombocytopeni (itp) hos vuxna patienter som är refraktära mot andra behandlingar.
nplate
amgen europe b.v. - romiplostim - purpura, trombocytopenisk, idiopatisk - hemostatika - adults:nplate is indicated for the treatment of primary immune thrombocytopenia (itp) in adult patients who are refractory to other treatments (e. kortikosteroider, immunoglobuliner). paediatrics:nplate is indicated for the treatment of chronic primary immune thrombocytopenia (itp) in paediatric patients one year of age and older who are refractory to other treatments (e. kortikosteroider, immunoglobuliner).
revolade
novartis europharm limited - eltrombopag - purpura, trombocytopenisk, idiopatisk - other systemic hemostatics, antihemorrhagics - revolade is indicated for the treatment of adult patients with primary immune thrombocytopenia (itp) who are refractory to other treatments (e. corticosteroids, immunoglobulins) (see sections 4. 2 och 5. revolade is indicated for the treatment of paediatric patients aged 1 year and above with primary immune thrombocytopenia (itp) lasting 6 months or longer from diagnosis and who are refractory to other treatments (e. corticosteroids, immunoglobulins) (see sections 4. 2 och 5. revolade is indicated in adult patients with chronic hepatitis c virus (hcv) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy (see sections 4. 4 and 5. revolade is indicated in adult patients with acquired severe aplastic anaemia (saa) who were either refractory to prior immunosuppressive therapy or heavily pretreated and are unsuitable for haematopoietic stem cell transplantation (see section 5.
hemlibra
roche registration limited - emicizumab - hemofili a - hemostatika - hemlibra is indicated for routine prophylaxis of bleeding episodes in patients with haemophilia a (congenital factor viii deficiency):with factor viii inhibitorswithout factor viii inhibitors who have:severe disease (fviii < 1%)moderate disease (fviii ≥ 1% and ≤ 5%) with severe bleeding phenotype. hemlibra kan användas i alla åldersgrupper.
eltrombopag glenmark 75 mg filmdragerad tablett
glenmark arzneimittel gmbh - eltrombopagolamin - filmdragerad tablett - 75 mg - isomalt hjälpämne; mannitol hjälpämne; eltrombopagolamin 95,7 mg aktiv substans
eltrombopag glenmark 12,5 mg filmdragerad tablett
glenmark arzneimittel gmbh - eltrombopagolamin - filmdragerad tablett - 12,5 mg - eltrombopagolamin 15,95 mg aktiv substans; isomalt hjälpämne; mannitol hjälpämne
eltrombopag glenmark 25 mg filmdragerad tablett
glenmark arzneimittel gmbh - eltrombopagolamin - filmdragerad tablett - 25 mg - isomalt hjälpämne; mannitol hjälpämne; eltrombopagolamin 31,9 mg aktiv substans